Related Experiment Video

Updated: May 27, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction?

Heiner K Berthold, Wilhelm Krone, Erland Erdmann

    European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
    |November 17, 2011
    PubMed

    Insights

    The Study of Heart And Renal Protection (SHARP) trial found that lipid-lowering treatment reduced vascular events in chronic kidney disease patients but did not improve survival. The study

    Area of Science:

    • Cardiovascular Medicine
    • Nephrology
    • Pharmacology

    Background:

    • The efficacy of lipid-lowering therapy in reducing cardiovascular events in patients with chronic kidney disease (CKD) remains debated.
    • Recent trials, including those in hemodialysis patients, have yielded inconclusive results regarding cardiovascular benefits.
    • The Study of Heart And Renal Protection (SHARP) trial investigated the impact of lipid-lowering treatment on vascular events in CKD patients.

    Discussion:

    • The SHARP trial demonstrated a 17% relative risk reduction in major vascular events for patients receiving simvastatin plus ezetimibe compared to placebo.
    • However, the trial did not show a significant benefit in terms of patient survival.
    • Concerns exist regarding the trial's design, specifically comparing a combination therapy against a placebo, which obscures the individual contributions of simvastatin and ezetimibe.

    Key Insights:

    • Lipid lowering with simvastatin and ezetimibe combination therapy significantly reduces vascular events in patients with chronic kidney disease.
    • The observed reduction in vascular events did not translate into improved overall survival in the studied CKD population.
    • The trial design limits the ability to determine whether statin therapy, ezetimibe, or their combination was primarily responsible for the observed benefits.

    Outlook:

    • Further research is needed to elucidate the specific roles of statins versus ezetimibe in managing cardiovascular risk in CKD patients.
    • Investigating the cost-effectiveness of different lipid-lowering strategies in CKD is crucial for clinical and economic decision-making.
    • Future trials could be designed to directly compare the efficacy and safety of statins and ezetimibe in this patient population.

    Related Concept Videos

    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

    In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
    Chronic Kidney Disease I: Introduction01:25

    Chronic Kidney Disease I: Introduction

    Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...